![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
Strategic guidance from trusted advisors to help your health system achieve more.
The Pros and Cons of the "Buy and Bill" Model
Leaders chime in on the benefits of the "buy and bill" model.
By
Date
January 26, 2022
By: MedSurg Editorial Team
Read time: 5 minutes
An alternative to the traditional "buy and bill" model of pharmaceutical distribution is bagging, which removes the financial burden from the provider because the specialty pharmacy or third-party payer must purchase the drug before it arrives in the provider's office. McKesson health systems leaders, Barbara Giacomelli and Valerie Russo provide insight on the benefits of the "buy and bill" model, and how to determine what's appropriate for your business.
Related Stories
Our Specialty Pharmacy Enablement expert shares insights on how health systems can boost access and outcomes by adopting integrated in‑house specialty pharmacy services.
Experts shared strategic insights to help health systems achieve more for the business of pharmacy.
Hear from our experts on how smarter scheduling and technology strengthen patient experience in health system infusion centers.
The most downloaded content by health system pharmacy leaders in December 2025.
This interactive checklist guides you through 10 critical questions that can help uncover next steps for your health system’s specialty pharmacy strategy.
Get to know one of our McKesson Health Systems pharmacy experts and industry-leading voices, Rafael Saenz.
Hospital leaders discuss ambulatory pharmacy strategies, 340B considerations, and value-based care optimization at McKesson's Becker's Roundtable session.
This interactive checklist guides you through 5 critical questions that can help uncover next steps for your health system’s infusion service line.
The most downloaded content by health system pharmacy leaders in November 2025.